Bank of America just raised its EUR/USD forecast
Tandem Diabetes Care, Inc. (NASDAQ:TNDM) stock has reached a new 52-week low, touching down to $18.27, marking a dramatic 66% decline from its 52-week high of $53.69. According to InvestingPro analysis, technical indicators suggest the stock is currently in oversold territory. This latest price movement underscores a challenging period for the medical device company, which has seen its stock price significantly retreat from higher levels over the past year. The company has experienced a steep 37% decline over the past year, with particularly concerning drops of 56% in the last six months. Despite these challenges, InvestingPro analysis indicates the stock is currently undervalued, with 12 analysts actively covering the company. The company maintains strong liquidity with a current ratio of 2.93, though analysts don’t expect profitability this year. For deeper insights, investors can access 13 additional exclusive ProTips and comprehensive analysis through InvestingPro’s detailed research report.
In other recent news, Tandem Diabetes Care has experienced a series of downgrades from multiple analyst firms following its latest financial disclosures and future guidance. Morgan Stanley (NYSE:MS) downgraded the stock to Equalweight from Overweight, citing concerns over the company’s modest revenue growth outlook and competitive pressures. The firm also reduced its price target to $22, highlighting the limited impact of anticipated catalysts like Type 2 label expansion. Similarly, Citi downgraded Tandem Diabetes to Neutral from Buy and set a new price target of $24, expressing uncertainty about the company’s growth trajectory despite a 20.6% revenue increase in the fourth quarter of 2024.
Bernstein also revised its rating to Market Perform from Outperform, setting a price target of $25 due to Tandem’s loss of market share and increased competition from new entrants like Beta Bionics. The company’s recent strategic shifts in U.S. sales expansion and distributor transitions overseas are seen as potential operational challenges. Despite a revenue boost in international sales, Tandem’s guidance for 2025 projects only a 10-11% increase, which has raised concerns among investors. Citi, while maintaining a Buy rating in a separate analysis, acknowledged the pressure on the stock due to the lower-than-expected guidance for the first quarter of 2025. These developments reflect a cautious outlook for Tandem Diabetes as it navigates a competitive and evolving market landscape.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.